Plant Name: Cicer arietinum
Taxonomic Information:
Plant ID: NPO7960
Plant Latin Name: Cicer arietinum
Taxonomy Genus: Cicer
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
3827
Plant-of-the-World-Online:
486336-1
Used in Medicines:
Country/Region:
Turkey; Italy; India; Jordan; Chile; China; ArgentinaTraditional Medicine System:
Sowa-Rigpa; Indian Folk; Unani; Siddha; Ayurveda; TCMMedicinal Functions:
Astringent
Geographical Distribution:
Turkey; Afghanistan; Italy; Bangladesh; Sudan; Nepal; Mongolia; France; Ethiopia; Somalia; Peru; Argentina; Ecuador; Turkmenistan; Australia; Iran; Algeria; Cuba; United States; Trinidad and Tobago; Zimbabwe; China; Chile; Jordan; Dominican Republic; Iraq; Kazakhstan; Ukraine; Mauritania; Uganda; Libya; Tanzania; Mauritius; Morocco; Belarus; Yemen; Russia; Pakistan; Angola; Myanmar; Mexico; Egypt; Cyprus; India; Uzbekistan; Tunisia; Colombia; Sri Lanka; Kenya; Taiwan; Fiji
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| RECQL; AKR1B1; HSD17B2; HSD17B10; ALDH1A1; TNKS; TNKS2; | |
| MAPK1; EGFR; | |
| CA12; CA7; CA4; | |
| THRB; | |
| KDM4E; | |
| HIF1A; TP53; NFKB1; | |
| RAB9A; NPC1; LMNA; MAPT; THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Nuclear hormone receptor subfamily 1 group A | THRB | Thyroid hormone receptor beta-1 | P10828 | CHEMBL1947 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.161E-14 | 4.705E-10 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.149E-09 | 5.396E-06 | AKR1B1, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, HSD17B2, NPC1 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.487E-09 | 5.396E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.487E-09 | 5.396E-06 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.240E-09 | 1.319E-05 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 9.733E-09 | 2.355E-05 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.364E-07 | 1.856E-04 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.904E-07 | 3.011E-04 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 4.771E-07 | 4.328E-04 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 8.484E-07 | 7.390E-04 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.096E-06 | 8.522E-04 | CA12, CA4, CA7 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 1.635E-06 | 1.148E-03 | MAPK1, TNKS, TNKS2 |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 2.185E-06 | 1.442E-03 | AKR1B1, HIF1A, MAPK1, MAPT |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.552E-06 | 1.588E-03 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.185E-06 | 1.875E-03 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.234E-06 | 2.388E-03 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 5.640E-06 | 2.995E-03 | CYP2D6, CYP3A4 |
| BP | GO:0007610; behavior | GO:0007610; behavior | 7.009E-06 | 3.469E-03 | EGFR, HIF1A, MAPK1, MAPT, NPC1, THRB, TP53 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.067E-05 | 5.018E-03 | CYP1A2, EGFR, MAPK1 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 1.127E-05 | 5.113E-03 | TNKS, TNKS2 |
| BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 1.416E-05 | 6.035E-03 | MAPK1, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 1.469E-05 | 6.035E-03 | AKR1B1, EGFR, MAPK1, TP53 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.686E-05 | 6.557E-03 | CA12, CA4, CA7 |
| CC | GO:0043226; organelle | GO:0043231; intracellular membrane-bounded organelle | 1.626E-05 | 6.556E-03 | AKR1B1, CA4, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, EGFR, HIF1A, HSD17B10, KDM4E, LMNA, MAPK1, MAPT, NFKB1, NPC1, RAB9A, RECQL, THRB, TNKS, TNKS2, TP53 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 2.558E-05 | 9.603E-03 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, EGFR, HSD17B2, RAB9A |
| CC | GO:0016020; membrane | GO:0031090; organelle membrane | 1.292E-04 | 3.162E-02 | CA4, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, EGFR, LMNA, NPC1, RAB9A, TNKS, TNKS2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 3.210E-08 | 4.278E-06 | CYP2C9, CYP2D6, CYP1A2, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 6.112E-08 | 4.278E-06 | CYP2C9, CYP1A2, CYP3A4, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.793E-06 | 4.444E-05 | MAPK1, TP53, EGFR, NFKB1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.685E-06 | 4.444E-05 | CYP2C9, CYP1A2, ALDH1A1, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.905E-06 | 4.444E-05 | MAPK1, TP53, HIF1A, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 5.946E-06 | 9.249E-05 | MAPK1, TP53, EGFR, NFKB1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.690E-06 | 5.379E-05 | CYP2C9, CYP2D6, CYP1A2, CYP3A4 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.063E-05 | 1.488E-04 | MAPK1, HIF1A, EGFR, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 4.287E-06 | 7.502E-05 | CYP2C9, CYP1A2, CYP3A4, CYP2C19 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04010 | MAPK signaling pathway | 2.079E-05 | 2.239E-04 | MAPK1, MAPT, TP53, EGFR, NFKB1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.481E-05 | 1.885E-04 | CYP2C9, CYP2D6, MAPK1, CYP2C19 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.473E-06 | 4.444E-05 | CA12, CA4, CA7 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 1.819E-05 | 2.123E-04 | THRB, MAPK1, TP53, HIF1A |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 3.562E-05 | 3.116E-04 | LMNA, MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 2.913E-05 | 2.719E-04 | MAPK1, TP53, EGFR, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 5.799E-05 | 4.510E-04 | MAPK1, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 2.260E-05 | 2.260E-04 | MAPK1, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 4.640E-05 | 3.821E-04 | MAPK1, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 9.064E-05 | 6.345E-04 | MAPK1, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.692E-04 | 9.476E-04 | MAPK1, HIF1A, TP53, EGFR, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.506E-04 | 9.166E-04 | MAPK1, TP53, HIF1A, EGFR |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.630E-04 | 9.476E-04 | CYP2C9, HSD17B2, CYP1A2, ALDH1A1, AKR1B1, CYP2C19, CYP3A4, HSD17B10 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.180E-04 | 7.864E-04 | MAPK1, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 1.281E-04 | 8.154E-04 | MAPK1, TP53, NFKB1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 6.443E-05 | 4.748E-04 | CYP1A2, HSD17B2, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 3.348E-04 | 1.803E-03 | MAPK1, HIF1A, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 6.387E-04 | 2.981E-03 | MAPK1, TP53, EGFR, NFKB1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 5.546E-04 | 2.773E-03 | MAPK1, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 5.546E-04 | 2.773E-03 | MAPK1, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 1.069E-03 | 4.401E-03 | MAPK1, TP53, EGFR, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 9.803E-04 | 4.159E-03 | MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 7.982E-04 | 3.492E-03 | RAB9A, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 2.589E-03 | 9.858E-03 | MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05010 | Alzheimer's disease | 1.468E-03 | 5.873E-03 | MAPK1, MAPT, HSD17B10 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 2.676E-03 | 9.858E-03 | MAPK1, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04621 | NOD-like receptor signaling pathway | 2.676E-03 | 9.858E-03 | MAPK1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 6.967E-04 | 3.146E-03 | MAPK1, TP53 |
| Unclassified | Unclassified | hsa04320 | Dorso-ventral axis formation | 6.033E-04 | 2.913E-03 | MAPK1, EGFR |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | MAPK1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
